Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)—a prospective single-arm interventional study

被引：0
|
作者：
Mikio Sugimoto
Takuma Kato
Yoichiro Tohi
Yosuke Shimizu
Ryuji Matsumoto
Takahiro Inoue
Yutaka Takezawa
Kimihiko Masui
Hiroshi Sasaki
Hiromi Hirama
Shiro Saito
Shin Egawa
Toshiyuki Kamoto
Satoshi Teramukai
Shinsuke Kojima
Takashi Kikuchi
Yoshiyuki Kakehi
机构：
[1] Kagawa University,Department of Urology, Faculty of Medicine
[2] Kobe City Nishi-Kobe Medical Center,Department of Urology
[3] Hokkaido University Graduate School of Medicine,Department of Urology
[4] Kyoto University,Department of Urology, Graduate School of Medicine
[5] Isesaki Municipal Hospital,Department of Urology
[6] Otsu City Hospital,Department of Urology
[7] Jikei University School of Medicine,Department of Urology
[8] National Hospital Organization Tokyo Medical Center,Department of Urology
[9] University of Miyazaki,Department of Urology, Faculty of Medicine
[10] Kyoto Prefectural University of Medicine,Department of Biostatistics
[11] Foundation for Biomedical Research and Innovation at Kobe Translational Research Center for Medical Innovation,undefined
来源：
BMC Urology | / 22卷
关键词：
Combined androgen blockade; Enzalutamide; Non-metastatic castration-resistant prostate cancer; Progression-free survival; Radical treatment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)-a prospective single-arm interventional study
    Sugimoto, Mikio
    Kato, Takuma
    Tohi, Yoichiro
    Shimizu, Yosuke
    Matsumoto, Ryuji
    Inoue, Takahiro
    Takezawa, Yutaka
    Masui, Kimihiko
    Sasaki, Hiroshi
    Hirama, Hiromi
    Saito, Shiro
    Egawa, Shin
    Kamoto, Toshiyuki
    Teramukai, Satoshi
    Kojima, Shinsuke
    Kikuchi, Takashi
    Kakehi, Yoshiyuki
    BMC UROLOGY, 2022, 22 (01)
  • [2] Sequential therapy with darolutamide in patients with non-metastatic castration-resistant prostate cancer resistant to enzalutamide or apalutamide
    Fujmoto, Saizo
    Fujita, Kazutoshi
    Nishimoto, Mitsuhisa
    Hamaguchi, Mamoru
    Kuwahara, Ken
    Hashimoto, Mamoru
    Adomi, Shogo
    Minami, Takafumi
    Nozawa, Masahiro
    Yoshimura, Kazuhiro
    Uemura, Hirotsugu
    CANCER MEDICINE, 2023, 12 (03): : 3176 - 3179
  • [3] Enzalutamide for patients with metastatic castration-resistant prostate cancer
    Ramadan, Wijdan H.
    Kabbara, Wissam K.
    Al Masri, Hiba S. Al Basiouni
    ONCOTARGETS AND THERAPY, 2015, 8 : 871 - 876
  • [4] Treatment and trials in non-metastatic castration-resistant prostate cancer
    Lokeshwar, Soum D.
    Klaassen, Zachary
    Saad, Fred
    NATURE REVIEWS UROLOGY, 2021, 18 (07) : 433 - 442
  • [5] New treatment standard for patients with non-metastatic castration-resistant prostate cancer
    Alekseev, B. Ya
    ONKOUROLOGIYA, 2018, 14 (03): : 68 - 77
  • [6] Effectiveness and safety of enzalutamide and apalutamide in the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC): a multicenter retrospective study
    Hara, Shuhei
    Mori, Keiichiro
    Fukuokaya, Wataru
    Tomomasa, Naoya
    Oguchi, Takahiro
    Takahashi, Yusuke
    Saito, Shun
    Katami, Jun
    Sano, Takayuki
    Kadena, Soushi
    Hashimoto, Masaki
    Yata, Yuji
    Nishi, Eriko
    Suhara, Yushi
    Takamizawa, Shigeyoshi
    Kurawaki, Shiro
    Suzuki, Hirotaka
    Miyajima, Keiichiro
    Iwatani, Kosuke
    Urabe, Fumihiko
    Ito, Kagenori
    Yanagisawa, Takafumi
    Tsuzuki, Shunsuke
    Shimomura, Tatsuya
    Kimura, Takahiro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (08) : 1191 - 1197
  • [7] Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide
    Gul, Anita
    Garcia, Jorge A.
    Barata, Pedro C.
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 7253 - 7262
  • [8] Current opportunities of therapy for patients with non-metastatic castration-resistant prostate cancer
    Alekseev, B. Ya
    Nushko, K. M.
    Kozlova, P. S.
    Kaprin, A. D.
    Mailyan, O., I
    ONKOUROLOGIYA, 2020, 16 (03): : 190 - 197
  • [9] Non-metastatic castration-resistant prostate cancer: management recommendations
    Alcaraz Asensio, A.
    Alvarez Ossorio, J. L.
    Cozar Olmo, J. M.
    Chantada Abal, V
    Juarez Soto, A.
    Espinos, E. Linares
    Moreno Jimenez, J.
    Munoz Rodriguez, J.
    Perez Fentes, D.
    Plata Bello, A.
    Rodrigo Aliaga, M.
    Unda Urzaiz, M.
    Vilaseca, A.
    ACTAS UROLOGICAS ESPANOLAS, 2022, 46 (04): : 193 - 213
  • [10] Apalutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
    Al-Salama, Zaina T.
    DRUGS, 2019, 79 (14) : 1591 - 1598
12345